GoodRx (NASDAQ:GDRX) Earns Hold (C-) Rating from Weiss Ratings

Key Points

• GoodRx's stock received a "hold (C-)" rating from Weiss Ratings, with analysts also noting an average price target of $5.80.
• The company reported earnings of $0.09 EPS for the quarter, which was below the consensus estimate of $0.10, as revenue increased by 1.2% year-over-year but was slightly below expectations.
• Institutional investors control 63.77% of GoodRx's stock, with several firms recently increasing their holdings in the company.

GoodRx (NASDAQ:GDRX - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities researchers at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

GDRX has been the topic of several other reports. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $5.80.

GoodRx Stock Performance

NASDAQ:GDRX opened at $4.39 on Wednesday. The business's 50-day moving average is $4.22 and its two-hundred day moving average is $4.39. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx has a 12 month low of $3.31 and a 12 month high of $7.18. The firm has a market capitalization of $1.53 billion, a PE ratio of 43.90, a price-to-earnings-growth ratio of 1.91 and a beta of 1.23.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. During the same period last year, the business earned $0.08 earnings per share. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Research analysts predict that GoodRx will post 0.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of GoodRx stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in the business. Hohimer Wealth Management LLC raised its holdings in shares of GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after buying an additional 2,748 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock valued at $85,000 after buying an additional 5,201 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after buying an additional 7,580 shares during the last quarter. Finally, Citizens Financial Group Inc. RI bought a new stake in shares of GoodRx during the first quarter valued at approximately $44,000. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.